Virometix further strengthens the Advisory Board
Zurich, Switzerland (April 12, 2016)
– Virometix today announced the addition of Dr. Martin L. Moore, an Assistant Professor at Emory University, Director of the Emory Children’s Center for Childhood Infections and Vaccines (CCIV) to its Advisory Board. Dr. Moore is a recognized leader in RSV research and has been running an NIH-funded laboratory in the Department of Pediatrics at Emory since 2008. His work on RSV vaccines was recognized as Emory University’s Innovation of the year in 2013.
Furthermore, the Advisory Board will be strengthened by the nomination of Dr. Urs Regenass, who has over 30 years’ experience in drug discovery. Most recently he worked as Senior Director Oncology at Actelion Pharmaceuticals. Before that Dr. Regenass was member of Novartis’ global research management board and VP Drug Discovery and CEO of the Switzerland site at Discovery Partners International, a CRO headquartered in San Diego. He obtained his PhD in Cell Biology at the Biocenter, University of Basel.
Virometix closes oversubscribed financing round
Zurich - Schlieren, Switzerland (October 26, 2015)
– Virometix today announced the closing of a new financing round, which involved existing shareholders as well as a new private investor and was oversubscribed. Virometix will use the proceeds from this financing round to expand its operations and advance its vaccine candidates for infectious and viral diseases.
Virometix extends its Board of Directors and appoints a new chairman
Zurich - Schlieren, Switzerland (July 27, 2015)
– Virometix today announced the appointment of Dr. Ivan Csendes as new independent Board member and Chairman of the Board of Directors. Dr. Csendes brings in a longstanding and broad expertise from the pharmaceutical industry, including 23 years work experience at the Business Development and Licensing Departments of Ciba-Geigy and Novartis, where he was responsible for in- and out-licensing of drug candidates as well as for various drug delivery and device projects. Dr Csendes is a founding member and Board member of Swiss Healthcare Licensing Group and member of the European Pharma Licensing Group. Dr. Csendes holds a PhD in Chemistry from the University of Basel, Switzerland.